Search Orphan Drug Designations and Approvals
-
| Generic Name: | synthetic double-strand small interfering ribonucleic acid (siRNA) oligonucleotide drug directed against C3 messenger RNA |
|---|---|
| Date Designated: | 11/22/2022 |
| Orphan Designation: | Treatment of C3 Glomerulopathy |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Silence Therapeutics plc 72 Hammersmith Rd. W14 8th London, England United Kingdom The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







